Global Metagenomic Sequencing Market - 2020-2027
|元基因組測序的全球市場：2020-2027 Global Metagenomic Sequencing Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
The global metagenomic sequencing market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Metagenomics is a research field where genomic analysis of microbial DNA from environmental communities is studied. Metagenomic sequencing techniques enable scientists to analyze genes in the given sample. The method allows researchers to assess bacterial diversity and identify the presence of microbes in various environments. Steps involved in metagenomics sequencing include DNA extraction, library preparation, sequencing, assembly, annotation and statistical analysis.
Advanced technological platforms and improved genomic tools
One of the major factor driving the growth of metagenomics sequencing market is the continuous development of faster sequencing techniques and advancements in different methods to cope with the huge data generated, which are expanding researchers' capacity to analyze microbial communities from an unlimited variety of environments.
The growing adoption of advanced bioinformatics tools, high throughput screening (HTS) methods, recovery of novel drugs, and development of cost-effective technologies such as next-generation sequencing (NGS) are driving the market growth. The development of Next Generation DNA Sequencing (NGS) technology has driven molecular biology research, leading to several discoveries and new insights. Next-generation DNA sequencing technology goes beyond long-established DNA sequencing with its applications that reach across the principles of molecular biology.
In May 28, 2019, precision medical biotechnology company, Macrogen, Inc. received South Korean accreditation of Good Clinical Lab Practices from the country's Ministry of Food and Drug Safety (MFDS) and designated as clinical trial specimen analysis institution. It would benefit Macrogen with improvised clinical diagnostic metagenomics.
Hence, increasing technological advancements regarding DNA sequencing is expected to drive market growth over the forecast period.
Increasing initiatives and funds by government and private organizations to large scale projects of sequencing
The growing awareness towards the genetic disorders and increasing government initiatives and funds to large scale projects of sequencing are among the major factor driving the growth of the global metagenomic sequencing market. For instance, in 2019, QIAGEN got into a partnership with multiple organizations in the UK to support and establish its global genomics campus in Manchester (UK). The new Genomic Health Innovation Campus will aim at innovation in life sciences, translational sciences, and the molecular diagnostics field.
Also, in November 2019, The "Million Microbiome of Humans Project" (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientists from China, France, Sweden, Denmark, Latvia and other countries will cooperate in microbial metagenomic research, aiming to sequence and analyze one million microbial samples from intestines, skin, mouth, reproductive tract and other organs in the next 3-5 years to draw a microbiome map of the human body and build the world's largest database of the human microbiome.
Factors hampering the growth of metagenomics sequencing market
However, the market growth is hampered by several factors such as growing concerns towards the standardization and accuracy of diagnostic testing, its requirement for parallel advancement in various isolation and identification techniques, more efficient & robust bioinformatics tools, and lack of skilled professionals.
COVID-19 Impact Analysis
The metagenomic sequencing market is positively impacted by COVID-19 as, throughout the COVID-19 pandemic, testing is a critical component of the response and rapidly increasing, which enables rapid identification and isolation of infected individuals. Majority of this testing is PCR-based, detecting the presence of the SARS-CoV-2 virus only.
Next-generation sequencing (NGS) of the COVID-19 virus is providing powerful metagenomic data, that is combined with clinical data to search for effective treatments. Continous genomic and epigenomic analysis of SARS-CoV-2 is critical, used to determine the number of virus strains, how the virus is spread into new regions, number of introductions of the virus if there is community spread of the virus if outbreaks are linked, and how the virus is evolving.
Oxford Nanopore Technologies is doing the Metagenomic analysis of SARS-CoV-2 respiratory samples via Sequence-Independent Single Primer Amplification (SISPA) and nanopore sequencing.
The global metagenomic sequencing market is segmented on the basis of product and service, technology , workflow, and application.
Sample processing & library preparation estimated to dominate the market
On the basis of workflow, the metagenomic sequencing market is classified as sample processing and library preparation, sequencing, data processing and analysis. Among these, sample processing and library preparation segment accounted for the largest segment in 2019, owing to the increasing number of metagenome sequencing research projects, wide availability of technically advanced and robust sample processing.
Reagents & consumables dominating the metagenomic sequencing market with the largest share in 2019
Based on products & services, the metagenomic sequencing market is segmented into instruments, reagents & consumables, analysis & data interpretation solutions, and services. Among these, the reagents & consumables accounted for the largest share of the market in 2019, due to growing demand for sequencing reagents by end-users and the development of high-quality reagents and kits.
By technology, shotgun metagenomic sequencing technology is expected to grow at fastest CAGR during the forecast period.
By technology, the metagenomic sequencing market is segmented into 16S rRNA sequencing, shotgun metagenomic sequencing, whole-genome sequencing & de-novo assembly, and metatranscriptomics. Out of all these segments, the shotgun metagenomic sequencing technology is growing at the fastest growth rate over the forecast period, due to growing adoption of shotgun metagenomic sequencing among researchers and healthcare professionals, several advantages offered by shotgun sequencing compared with other techniques, and the increasing number of metagenomic sequencing-based research activities. Shotgun sequencing can detect low abundance members of microbial communities. Shotgun metagenome sequencing can target all genes from all organisms found in an environmental sample, in contrast to the whole sequencing and targeting all genes from only one organism.
The drug discovery segment of applications accounted for the largest share in 2019
On the basis of applications, the metagenomic sequencing market is classified into clinical diagnostics, drug discovery, industrial applications , veterinary application, soil microbiome applications, ecological and environmental applications, and others. Among these, the drug discovery segment accounted for the largest share in 2019, owing to the rising number of research activities for novel drug discovery, increasing collaborations among major players, pharmaceutical companies, and academic institutions for drug development, and growing use of metagenomic NGS in clinical trials.
North America region holds the largest market share in global Metagenomic Sequencing market
North America region is dominating the global metagenomic sequencing market accounted for the largest market share in 2019, owing to technological advancements in the next-generation sequencing procedures along with its increasing applications, favourable initiatives by government and private bodies for the development and adoption of NGS-based metagenomics technologies, the wide adoption of metagenomic diagnostics in the region, and rising awareness of metagenomics sequencing services. The market players are collaborating to introduce new procedures with innovative technology. For instance, In 2019, Illumina and Thermo Fisher Scientific (U.S.) entered into a commercial agreement for the sales of Thermo Fisher's Ion AmpliSeq technology to researchers who use Illumina's NGS platforms.
Europe market is growing significantly with increasing collaboration and projects related to metagenomic sequencing
The European market accounted for the second-largest share in the global metagenomic sequencing market due to the growing investment by the government and hospital facilities, increasing collaborations and partnerships by major players, and growing adoption of NGS procedure by research laboratories.
In July 2020, Australian microbial genetics firm Microba has signed an agreement with German medical diagnostic services provider Synlab to launch a gut microbiome test, MyBiome, in Europe and Latin America. The test measures bacterial species in the gut microbiome and calculates their metabolic potential in relation to healthy reference ranges. The product launch will bring its whole-genome metagenomic sequencing and bioinformatics software to new markets, and Synlab will make a new gastrointestinal testing service available to its network of doctors and clinics.
In 2016, QIAGEN N.V. acquired Exiqon A/S (Denmark) which helped QIAGEN leverage Exiqon's advanced Locked Nucleic Acid (LNA) technology to improve the sensitivity of PCR and NGS assays.
Asia-Pacific region is growing at the fastest CAGR during the forecast period
The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period, due to the rising prevalence of genetic disorders and an increasing number of research projects. Major players are focusing on this region and investing money to expand their network that is helping them to capture a major piece of the market. In 2019, Illumina and KingMed Diagnostics (China) partnered to co-develop oncology & hereditary disease testing applications based on Illumina's NGS technology.
The metagenomic sequencing market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., BGI Group, DNAstar, Inc., Eurofins Scientific, Macrogen, Inc., Oxford Nanopore Technologies Ltd., Brooks Automation, Inc. (GENEWIZ), Perkinelmer, Inc., among others.
Overview: llumina, Inc. was incorporated in April 1998 and headquarter located in San Diego, California. The company develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets.
Product Portfolio: The company's product portfolio includes a wide range of highly interconnected products, including sequencing, genotyping, gene expression, and molecular diagnostic products. Illumina also offers metagenomic sequencing services, which further strengthens its market position.
Key Development: In 2019, Illumina and Lundbeck Foundation GeoGenetics Centre (Denmark) collaborated to generate one of the largest ancient genome datasets. This partnership will also help explore the relationship between the evolutionary history of select mental & neurological disorders and infectious pathogens.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the metagenomic sequencing market globally. For instance,
The global metagenomic sequencing market report would provide an access to an approx. 69 market data table, 69 figures and 300 pages.
LIST NOT EXHAUSTIVE